These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration. Tobia C; Chiodelli P; Barbieri A; Buraschi S; Ferrari E; Mitola S; Borsani G; Guerra J; Presta M Front Immunol; 2019; 10():1092. PubMed ID: 31156639 [TBL] [Abstract][Full Text] [Related]
47. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies. Khare T; Bissonnette M; Khare S Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991 [TBL] [Abstract][Full Text] [Related]
48. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12. Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765 [TBL] [Abstract][Full Text] [Related]
49. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3. Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219 [TBL] [Abstract][Full Text] [Related]
50. Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization. Vestal RD; LaJeunesse DR; Taylor EW Curr Top Med Chem; 2016; 16(13):1427-40. PubMed ID: 26369825 [TBL] [Abstract][Full Text] [Related]
51. CXCR7 as a novel therapeutic target for advanced prostate cancer. Gritsina G; Yu J Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058 [TBL] [Abstract][Full Text] [Related]
52. Decreased ACKR3 (CXCR7) function causes oculomotor synkinesis in mice and humans. Whitman MC; Miyake N; Nguyen EH; Bell JL; Matos Ruiz PM; Chan WM; Di Gioia SA; Mukherjee N; Barry BJ; Bosley TM; Khan AO; Engle EC Hum Mol Genet; 2019 Sep; 28(18):3113-3125. PubMed ID: 31211835 [TBL] [Abstract][Full Text] [Related]
53. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762 [TBL] [Abstract][Full Text] [Related]
54. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878 [TBL] [Abstract][Full Text] [Related]
55. Effects of Small Molecule Ligands on ACKR3 Receptors. Hopkins BE; Masuho I; Ren D; Iyamu ID; Lv W; Malik N; Martemyanov KA; Schiltz GE; Miller RJ Mol Pharmacol; 2022 Sep; 102(3):128-138. PubMed ID: 35809897 [TBL] [Abstract][Full Text] [Related]
56. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. Janssens R; Mortier A; Boff D; Ruytinx P; Gouwy M; Vantilt B; Larsen O; Daugvilaite V; Rosenkilde MM; Parmentier M; Noppen S; Liekens S; Van Damme J; Struyf S; Teixeira MM; Amaral FA; Proost P Biochem Pharmacol; 2017 May; 132():92-101. PubMed ID: 28322746 [TBL] [Abstract][Full Text] [Related]
57. Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle. Albee LJ; LaPorte HM; Gao X; Eby JM; Cheng YH; Nevins AM; Volkman BF; Gaponenko V; Majetschak M Open Biol; 2018 Jan; 8(1):. PubMed ID: 29386406 [TBL] [Abstract][Full Text] [Related]
58. Mode of binding of the cyclic agonist peptide TC14012 to CXCR7: identification of receptor and compound determinants. Montpas N; Cabana J; St-Onge G; Gravel S; Morin G; Kuroyanagi T; Lavigne P; Fujii N; Oishi S; Heveker N Biochemistry; 2015 Feb; 54(7):1505-15. PubMed ID: 25669416 [TBL] [Abstract][Full Text] [Related]
59. CXCR7, CXCR4 and CXCL12: an eccentric trio? Thelen M; Thelen S J Neuroimmunol; 2008 Jul; 198(1-2):9-13. PubMed ID: 18533280 [TBL] [Abstract][Full Text] [Related]
60. Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239. Richard-Bildstein S; Aissaoui H; Pothier J; Schäfer G; Gnerre C; Lindenberg E; Lehembre F; Pouzol L; Guerry P J Med Chem; 2020 Dec; 63(24):15864-15882. PubMed ID: 33314938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]